Seroprevalence of seven high-risk HPV types in The Netherlands |
| |
Authors: | Mirte Scherpenisse Madelief Mollers Rutger M. Schepp Hein J. Boot Hester E. de Melker Chris J.L.M. Meijer Guy A.M. Berbers Fiona R.M. van der Klis |
| |
Affiliation: | 1. Laboratory for Infectious Diseases and Screening, National Institute of Public Health and the Environment, Bilthoven, The Netherlands;2. Department of Epidemiology and Surveillance, National Institute of Public Health and the Environment, Bilthoven, The Netherlands;3. Department of Pathology, VU University Medical Centre, Amsterdam, The Netherlands |
| |
Abstract: |
BackgroundTo obtain insight into the age-specific seroprevalence for seven high-risk human papillomavirus (hr-HPV) serotypes (HPV16, 18, 31, 33, 45, 52, and 58) among the general population in the pre-vaccination era in The Netherlands.MethodsFrom a cross-sectional population-based study (ISRCTN 20164309) performed in 2006/2007 6384 sera of men, women and children were tested for seven hr-HPV specific antibodies using a fluorescent bead-based multiplex immunoassay with virus-like particles of the seven HPV serotypes.ResultsAn increase in seroprevalence was observed in adolescents, especially for the most prevalent HPV type 16 (up to 11.3%). The increase was most pronounced in women, but was less clear for the other six HPV serotypes. Relatively stable seroprevalences were found in the middle aged cohorts and a slight decrease in the elderly. For the age cohorts >14 years, the seroprevalence among women (25.2%) was higher compared with men (20.3%) (p = 0.0002). We found that 10.1% of the population was seropositive for multiple HPV serotypes.ConclusionsThe HPV vaccination program is targeted at preadolescents as is justified by the results in this study in which a step-up in HPV seroprevalence is observed at ages of sexual debut. Although direct interpretation of seroprevalence data are hampered by cross-reactivity and seroconversion rate, these data are useful as baseline to evaluate long-term population effects of the HPV16/18 vaccination program. |
| |
Keywords: | HPV Seroprevalence High-risk Antibody concentrations The Netherlands |
本文献已被 ScienceDirect 等数据库收录! |
|